A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

Active:	Yes
Cancer Type:	Breast Cancer Unknown Primary	NCT ID:	NCT06926920
Trial Phases:	Phase I Phase II	Protocol IDs:	GS-US-576-7321 (primary) NCI-2025-05319 2024-519124-25
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Gilead
NCI Full Details:	http://clinicaltrials.gov/show/NCT06926920

Summary

The goal of this clinical study is to learn more about the study drug sacituzumab
govitecan-hziy (SG) given at an alternative dose and schedule, in participants with
triple-negative breast cancer (TNBC).

The primary objectives of this study are to assess the safety and tolerability of SG
given at alternate dose and schedule, to assess the effect on objective response rate
(ORR) and progression-free survival (PFS).

Objectives

Phase 1 of this study will evaluate the preliminary safety, tolerability,
pharmacokinetics (PK), and efficacy of SG. Phase 2 expansion of this study will further
evaluate the safety, efficacy, and PK of SG.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.